Sigyn Therapeutics Announces Second Quarter 2022 Financial Results
August 15, 2022 09:40 ET
|
Sigyn Therapeutics, Inc.
SAN DIEGO, CA, Aug. 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (OTCQB: SIGY), a development-stage company focused on the creation of therapeutic solutions that address...
Sigyn Therapeutics to Commence Trading on the OTCQB® Venture Exchange
August 03, 2022 06:30 ET
|
Sigyn Therapeutics, Inc.
SAN DIEGO, CA, Aug. 03, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTCQB: SIGY), a development-stage medical technology company focused on addressing unmet needs in global...
Sigyn Therapeutics Appoints Donald J. Hillebrand, M.D. to its Scientific Advisory Board
April 26, 2022 08:00 ET
|
Sigyn Therapeutics, Inc.
SAN DIEGO, CA, April 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (OTC Markets:“SIGY”), a medical technology company focused on the treatment of pathogen-associated...
Sigyn Therapeutics Appoints Ajay Verma, M.D., Ph.D. to its Scientific Advisory Board
March 31, 2022 08:30 ET
|
Sigyn Therapeutics, Inc.
SAN DIEGO, CA, March 31, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (OTC Markets:“SIGY”), a medical technology company focused on the treatment of pathogen-associated...
Sigyn Therapeutics Announces Filing of 2021 Annual Report on Form 10-K
March 22, 2022 08:00 ET
|
Sigyn Therapeutics, Inc.
SAN DIEGO, CA, March 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire --Sigyn Therapeutics, Inc. (OTC Markets: “SIGY”) (“Sigyn Therapeutics” or the “Company”), a medical technology company focused...
Sigyn Therapeutics™ Appoints H. David Humes, MD to Its Scientific Advisory Board
March 15, 2022 09:00 ET
|
Sigyn Therapeutics, Inc.
SAN DIEGO, CA, March 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTC Markets:“SIGY”), a medical technology company focused on the treatment of pathogen-associated...
Sigyn Therapeutics Appoints Alexander S. Yevzlin, MD, FASN to Its Scientific Advisory Board
March 09, 2022 09:00 ET
|
Sigyn Therapeutics, Inc.
SAN DIEGO, CA, March 09, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTC Markets: “SIGY”), a medical technology company focused on the treatment of pathogen-associated...
Sigyn Therapeutics™ Appoints Accomplished Financial Executive, Jeremy Ferrell, as Chief Financial Officer
March 02, 2022 08:00 ET
|
Sigyn Therapeutics, Inc.
SAN DIEGO, CA, March 02, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTC Markets:“SIGY”), a medical technology company focused on the treatment of pathogen-associated...
Sigyn Therapeutics™ Announces Completion of Animal Studies
February 23, 2022 08:00 ET
|
Sigyn Therapeutics, Inc.
Sigyn Therapy™ Safe and Well Tolerated During Six-hour Treatments SAN DIEGO, CA, Feb. 23, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTC Markets:“SIGY”), a medical...
Sigyn Therapeutics to Present at the Bullseye Small Cap Virtual Investor Conference
January 25, 2022 08:00 ET
|
Sigyn Therapeutics, Inc.
SAN DIEGO, Jan. 25, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (OTC Markets:“SIGY”), a medical technology company focused on the treatment of pathogen-related conditions...